Key Takeaways
- Primary Catalyst: Profound Medical Corp. (PROF) expects preliminary unaudited third-quarter 2026 revenue of $9.8 million to $10.0 million, exceeding Bloomberg’s mean analyst consensus by approximately 45% to 47%.
- Session Performance: PROF is up 21.65% today, with a current price of $6.91.
- Macro Environment: The broader market is experiencing a mixed session, with the S&P 500 and Nasdaq up 0.5% and 0.7% respectively, while the Dow Jones is flat.
| Metric | Detail |
|---|---|
| Asset / Ticker | PROF (Profound Medical Corp.) |
| Current Price | $6.91 |
| Session Movement | +21.65% |
| Category | Market-Movers |
The Catalyst Driving Today’s Movement
The primary catalyst driving today’s movement in PROF is the company’s announcement of strong preliminary third-quarter 2026 revenue. According to the company’s press release, PROF expects unaudited revenue of $9.8 million to $10.0 million for the three months ended September 30, 2026, representing a significant increase of approximately 85% to 89% year over year and 292% to 300% sequentially.
This announcement has sent shockwaves through the market, with PROF’s stock price surging 21.65% to $6.91. The company’s expected revenue is also significantly above Bloomberg’s mean analyst consensus, which is a testament to the strength of PROF’s commercial operations and scale.
Financial Fundamentals & Filings
As per the company’s Form 8-K filing, the expected revenue range is approximately 45% to 47% above Bloomberg’s mean analyst consensus of $6.78 million. Additionally, the company expects gross margin to exceed 70%, reflecting continued progress in its commercial operations and scale.
The company’s CEO and Chairman, Arun Menawat, has stated that the significant increase in revenue is a reflection of the strong commercial momentum building behind the company’s technology. Menawat also emphasized that the company remains focused on supporting customer adoption, increasing utilization of its installed base, and building a profitable growth company over the long-term.
Market Anchors & Sector Sentiment
The market reaction to PROF’s announcement is a testament to the strength of the company’s commercial operations and scale. The company’s expected revenue is significantly above analyst expectations, and the stock price has responded accordingly.
In terms of sector sentiment, the market is experiencing a mixed session, with the S&P 500 and Nasdaq up 0.5% and 0.7% respectively, while the Dow Jones is flat. However, PROF’s stock price is bucking this trend, with a significant gain of 21.65%.
Volume Dynamics & Volatility
The trading volume in PROF is significantly higher than usual, with over 36.5 million shares traded today. This is a testament to the market’s enthusiasm for the company’s announcement and the potential for future growth.
In terms of volatility, the stock price has experienced significant fluctuations over the past 12 months, with a 1-year change of -12.1% and a 1-month change of -17.6%. However, today’s movement is a significant departure from this trend, with a gain of 21.65%.
Macro Context
The broader market is experiencing a mixed session, with the S&P 500 and Nasdaq up 0.5% and 0.7% respectively, while the Dow Jones is flat. However, PROF’s stock price is bucking this trend, with a significant gain of 21.65%.
Financial Performance
The company’s expected revenue is a significant increase from the previous quarter, with a sequential quarter-over-quarter growth of approximately 292% to 300%. Additionally, the company’s gross margin is expected to exceed 70%, reflecting continued progress in its commercial operations and scale.
Conclusion
The market reaction to PROF’s announcement is a testament to the strength of the company’s commercial operations and scale. The company’s expected revenue is significantly above analyst expectations, and the stock price has responded accordingly. As the company continues to execute on its growth strategy, investors can expect further upside in the stock price.
FAQ
What is the current stock price of Profound Medical (PROF)?
The current stock price of Profound Medical (PROF) is $6.91.
What is the expected revenue range for Profound Medical (PROF) in Q3 2026?
Profound Medical (PROF) expects unaudited revenue of $9.8 million to $10.0 million for the three months ended September 30, 2026.
What is the expected gross margin for Profound Medical (PROF) in Q3 2026?
Profound Medical (PROF) expects gross margin to exceed 70%.
When will Profound Medical (PROF) report its full Q3 2026 results?
Profound Medical (PROF) intends to report full Q3 2026 results after market close on November 5, 2026.
The content on NovelStartup is for informational purposes only and does not constitute professional financial advice. Consult a certified financial advisor before making any major financial decisions.